Workflow
青岛蔚蓝生物股份有限公司 2025年半年度募集资金存放与 实际使用情况的专项报告
Zheng Quan Ri Bao·2025-08-27 23:25

Fundraising Overview - The company raised a total of RMB 394,016,730.00 from its initial public offering (IPO) by issuing 38,667,000 shares at RMB 10.19 per share, with a net amount of RMB 347,440,291.00 after deducting issuance costs [1][2] - For the non-public offering, the company raised RMB 499,999,984.00 at a price of RMB 19.69 per share, resulting in a net amount of RMB 495,954,700.96 after deducting issuance costs [2][3] Fund Management - The company has established a fundraising management method to ensure the proper management and use of raised funds, in compliance with relevant laws and regulations [3][4] - The company has signed tripartite supervision agreements with banks to manage the special accounts for the raised funds [5][8] Fund Usage - As of June 30, 2025, the company has used RMB 346,338,200.00 from the IPO funds and RMB 498,098,300.00 from the non-public offering funds [10][12] - The company has not used any idle funds for temporary working capital or for cash management during the reporting period [11][13] Project Changes - The company has made changes to its fundraising projects, including reallocating unused funds from the "Annual Production of 10,000 Tons of Plant Microecological Preparations" project to new projects [14][15][16] - The company has also approved the completion of certain projects and the permanent allocation of surplus funds to working capital [12][13] Disclosure Compliance - The company has complied with the disclosure requirements set by the China Securities Regulatory Commission, ensuring timely and accurate reporting of the fundraising and usage status [17]